Precision Medicine

Experic and Flurry Powders form a strategic alliance to accelerate complex therapies by combining advanced particle engineering with GMP manufacturing.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A groundbreaking study proves a botanical compound enhances protein absorption, leading to measurable gains in muscle strength and mass, especially for older adults.

RA Capital's major investment extends Karyopharm's runway, but future funding is now directly tied to the outcome of its pivotal endometrial cancer trial.

With positive safety data for its novel UC drug, a €530M cash reserve, and a new commercial chief, Abivax is poised for a major market entry.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

New research reveals a startling link between common liver conditions and heart failure in older adults with atrial fibrillation, urging a new look at risk.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.

IntraBio's landmark FDA submission for levacetylleucine offers the first glimmer of an approved therapy for the devastating rare disease Ataxia-Telangiectasia.

An influential guidelines update expands options for a tough-to-treat bladder cancer, giving patients access to a novel gene therapy beyond its FDA label.

The University of Miami launches a new program to arm doctors with business skills, addressing a critical leadership gap in the evolving healthcare industry.

A new oral drug is being tested with existing therapies, offering a two-pronged attack on the glycogen buildup that defines this debilitating rare disease.

With pivotal trials advancing, key FDA alignment, and a strong cash position, Taysha Gene Therapies charts a clear path toward a potential breakthrough.

A novel blood test from C2N Diagnostics, used in a major Alzheimer's trial, shows promise in predicting disease progression, heralding a new era of precision medicine.

Endevica Bio launches Kalohexis, a new biotech aiming to disrupt the obesity market with a drug that resets the body's 'metabolic thermostat'.

With a new CFO who helped steer a multi-billion dollar acquisition, Bambusa Therapeutics signals major growth plans for its innovative antibody platform.

As its new obesity drug enters a key trial, Biohaven bets on a novel approach: reducing fat while preserving precious muscle mass. Can it redefine weight loss?

Belief BioMed's single-dose treatment for hemophilia B, BBM-H901, is now approved in Macao, offering a new horizon for patients beyond frequent injections.

A new DoD-funded trial combines a biologic drug with a plant-based supplement, aiming to break treatment barriers for ulcerative colitis, a major military issue.